{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:33:45Z","timestamp":1763768025404,"version":"3.41.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Rifampicin is a strong inducer of the hepatic cytochrome P450 (CYP) family and is known to interact with many clinical drugs. However, to our knowledge, no case of worsening heart failure (HF) due to the interaction between rifampicin and HF drugs has been reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>A 32-year-old female, who had undergone intracardiac repair for an incomplete atrioventricular septal defect with dextrocardia and prosthetic valve replacements for right and left atrioventricular valve regurgitation, presented as an outpatient. Her medications included tolvaptan 15\u2005mg and warfarin 1.25\u2005mg. She had a slight fever and Osler nodes at her fingers. Blood culture bottles grew methicillin-resistant Staphylococcus epidermidis, and several vegetations were observed on the right atrioventricular mechanical valve with a transoesophageal echocardiogram. She was diagnosed with prosthetic valve endocarditis and treated with antibiotic agents including rifampicin. After a week, she developed systemic oedema and had a marked decrease in prothrombin time\u2013international normalized ratio (PT-INR). Rifampicin was promptly discontinued due to a strong suspicion of a drug\u2013drug interaction. Consequently, both her congestion and the PT-INR stabilized, and she was discharged after 8 weeks of antibiotic treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>The introduction of rifampicin induces CYP family members such as CYP3A4 and CYP2C9. Warfarin is metabolized by CYP2C9 and tolvaptan is also metabolized by CYP3A4, resulting in a notable reduction of their blood levels when co-administered with rifampicin. The clinical challenges arising from interactions between HF drugs and rifampicin can be categorized into two main groups: worsening HF and thrombotic complications. Clinicians should remain vigilant and informed about these potential issues.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytae525","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T09:09:06Z","timestamp":1727082546000},"source":"Crossref","is-referenced-by-count":1,"title":["A case report: pitfalls in antibacterial therapy with rifampicin for mechanical valve endocarditis\u2014the king of drug interactions"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9105-3463","authenticated-orcid":false,"given":"Ryosuke","family":"Honda","sequence":"first","affiliation":[{"name":"Department of Cardiology, Pulmonology, Hypertension, and Nephrology, Ehime University Graduate School of Medicine , Toon, Ehime, 791-0295 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-3565","authenticated-orcid":false,"given":"Yusuke","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, Hypertension, and Nephrology, Ehime University Graduate School of Medicine , Toon, Ehime, 791-0295 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuji","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, Hypertension, and Nephrology, Ehime University Graduate School of Medicine , Toon, Ehime, 791-0295 ,","place":["Japan"]},{"name":"Department of Community Emergency Medicine, Ehime University Graduate School of Medicine , Yawatahama, Ehime, 796-8502 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Higaki","sequence":"additional","affiliation":[{"name":"Department of Regional Pediatrics and Perinatology, Ehime University Graduate School of Medicine , Toon, Ehime, 791-0295 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, Hypertension, and Nephrology, Ehime University Graduate School of Medicine , Toon, Ehime, 791-0295 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"2024102315392083500_ytae525-B1","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","article-title":"2023 ESC guidelines for the management of endocarditis","volume":"44","author":"Delgado","year":"2023","journal-title":"Eur Heart J"},{"key":"2024102315392083500_ytae525-B2","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dky152","article-title":"Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis","volume":"73","author":"Stott","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2024102315392083500_ytae525-B3","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1128\/AAC.46.3.900-903.2002","article-title":"Penetration of rifampin through Staphylococcus epidermidis biofilms","volume":"46","author":"Zheng","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102315392083500_ytae525-B4","doi-asserted-by":"crossref","first-page":"e00959","DOI":"10.1128\/AAC.00959-19","article-title":"In vitro activity of rifampin, rifabutin, rifapentine, and Rifaximin against planktonic and biofilm states of staphylococci isolated from periprosthetic joint infection","volume":"63","author":"Albano","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102315392083500_ytae525-B5","doi-asserted-by":"crossref","first-page":"e01746","DOI":"10.1128\/AAC.01746-18","article-title":"Role of rifampin against staphylococcal biofilm infections in vitro, in animal models, and in orthopedic-device-related infections","volume":"63","author":"Zimmerli","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024102315392083500_ytae525-B6","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1172\/JCI3703","article-title":"The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions","volume":"102","author":"Lehmann","year":"1998","journal-title":"J Clin Invest"},{"key":"2024102315392083500_ytae525-B7","first-page":"849","article-title":"Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays","volume":"299","author":"Rae","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"2024102315392083500_ytae525-B8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2050-6511-14-27","article-title":"Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature","volume":"14","author":"Martins","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"2024102315392083500_ytae525-B9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","article-title":"Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects","volume":"73","author":"Shoaf","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"2024102315392083500_ytae525-B10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytae525\/59238370\/ytae525.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/8\/10\/ytae525\/60007305\/ytae525.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/8\/10\/ytae525\/60007305\/ytae525.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:39:40Z","timestamp":1729697980000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytae525\/7765168"}},"subtitle":[],"editor":[{"given":"Filippo","family":"Puricelli","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Rita","family":"Pavasini","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Marianna","family":"Garcia-Saldivia","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Maria Isabel","family":"Gonzalez Del Hoyo","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytae525","relation":{},"ISSN":["2514-2119"],"issn-type":[{"type":"electronic","value":"2514-2119"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,9,23]]},"article-number":"ytae525"}}